Shares of Hims & Hers Health tumbled 8.0% to $31.09 on Monday as investors digested the weight of a Federal Trade Commission lawsuit that strikes at the core of how the company signs up, bills, and retains its customers. Hims & Hers Promised Discretion, Then Allegedly Shared Your Health Data — How Deep Does the Damage Go?
Shares of Hims & Hers Health slid 8.0% to $31.09 Monday as Wall Street continued to reprice the telehealth company in the wake of a sweeping federal lawsuit that targets the very mechanics of how it signs up, bills, and retains its nearly 2.9 million subscribers. The stock has been whipsawed since the FTC filed its complaint on July 29, when shares initially cratered 14.7% to close at $25.00 on the day the lawsuit was announced .
The Government Says the Business Model Itself Is the Problem. The complaint alleges that Hims shared consumers' sensitive health information with third-party advertising platforms, including Meta and Snap, despite marketing its services as private and discreet . The FTC also claims Hims charged customers for prescription subscriptions shortly after they completed online intake forms, even though consumers were led to believe they would first consult with a healthcare provider . For a company whose brand depends on trust around embarrassing health conditions — hair loss, erectile dysfunction, weight loss — this strikes at the heart of the value proposition.
The Financial Exposure Goes Beyond Fines. In May, Hims disclosed a $15 million probable-loss accrual related to the matter, warning the final cost could be materially higher . The company faces risks including a permanent injunction, monetary penalties, and increased regulatory scrutiny over its data-sharing and subscription practices . At least one law firm has launched a separate securities investigation into whether management adequately disclosed the regulatory exposure to investors . A secondary wave of shareholder litigation could compound costs.
Fast Growth Hasn't Made the Problem Go Away. Hims reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, with subscribers at 2.891 million and monthly revenue per subscriber of $92 . Management raised full-year revenue guidance to $3.1–$3.3 billion . But for investors, the key issue is not only potential fines or settlements, but whether any required changes to marketing, data practices, or billing could raise costs or slow customer acquisition for a company that lives and dies by subscription growth.
The Company Is Fighting Back — But the Clock Is Ticking. Hims rejected the claims, saying the lawsuit ignores evidence provided during a nearly three-year investigation and characterized it as "an effort to generate headlines at our expense" . Bravado aside, the lawsuit could become one of the most significant consumer-protection cases in the telehealth space , potentially reshaping how every online healthcare company designs intake forms, billing, and ad-tracking. Investors aren't just pricing a fine — they're pricing a potential overhaul of the growth engine itself.